(70) Toward the Synthesis of New Potential Anti-Cancer Drugs

     Previous research has shown that a ruthenium complex of indazole (trans-[RuCl4(ind)2]-), known as KP1019, had possible usage as an anti-cancer drug. These initial findings suggested that related complexes could be... [ view full abstract ]

     Previous research has shown that a ruthenium complex of indazole (trans-[RuCl₄(ind)₂]^-), known as KP1019, had possible usage as an anti-cancer drug. These initial findings suggested that related complexes could be worth investigating. Toward that end, we have begun to design a variety of potential bidentate indazole ligands derived from indazole-3-carboxylic acid (I3C). Using I3C, we formed two different ligands and, using an iron center as a model of complexation, observed their similarities and differences using methods such as NMR and IR spectroscopy as well as melting point data. This effort began with the conversion of the IC3 into an intermediate ester, and then reduction to generate either an amine or a hydroxyl moiety as a second binding point linked to an indazole. Iron complexes derived from these ligands might be used for anti-cancer testing.